A B S T R A C T Human Factor IX (Christmas factor) is a single-chain plasma glycoprotein (mol wt 57,000) that participates in the middle phase of the intrinsic pathway of blood coagulation. It is present in plasma as a zymogen and is converted to a serine protease, Factor IXao, by Factor XIa (activated plasma thromboplastin antecedent) in the presence of calcium ions. In the activation reaction, two internal peptide bonds are hydrolyzed in Factor IX. These cleavages occur at a specific arginyl-alanine peptide bond and a specific arginyl-valine peptide bond. This results in the release of an activation peptide (mol wt-11,000) from the internal region of the precursor molecule and the generation of Factor IXaO (mol wt -46,000). Factor IXa, is composed ofa light chain (mol wt -18,000) and a heavy chain (mol wt -28,000), and these chains are held together by a disulfide bond(s). The light chain originates from the amino terminal portion of the precursor molecule and has an amino terminal sequence of Tyr-Asn-Ser-Gly-Lys. The heavy chain originates from the carboxyl terminal region of the precursor molecule and contains an amino terminal sequence of Val-Val-Gly-Gly-Glu. The heavy chain of Factor IXa, also contains the active site sequence of Phe-Cys-Ala-Gly-Phe-His-Glu-Gly -Gly -Arg -Asp -SerCys-Gln-Gly-Asp-SER-Gly-Gly-Pro. The active site serine residue is shown in capital letters. Factor IX is also converted to Factor IXa,,: by a protease from Russell's viper venom. This activation reaction, however, occurs in a single step and involves only the cleavage of the internal arginyl-valine peptide bond. Human Factor IX,,3 was inhibited by human antithrombin III by the formation of a one-to-one complex of enzyme and inhibitor. In this reaction, the inhibitor was tightly bound to the heavy chain of the enzyme. These data indicate that the mechanism of activation of human Factor IX and its inhibition by antithrombin III is essentially identical to that previously shown for bovine Factor IX.
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INTRODUCTION
Human Factor IX (Christmas factor)' is one of'the three vitamin K-dependent plasma proteins that participate in the intrinsic pathway of blood coagulation (1) . During the generation of' fibrin, Factor IX, a zymogen, is converted to a serine protease called Factor IXa. In the presence of Factor VIIIa (activated antihemophilic factor), phospholipid, and calcium ions, Factor IXa then converts Factor X (Stuart factor) to Factor Xa.
The purification of human Factor IX has been reported by a number of different investigators (2) (3) (4) (5) (6) (7) . It is a single-chain glycoprotein with mol wt 57,000. Human Factor IX, as well as bovine Factor IX, also contains y-carboxyglutamic acid which is characteristic of the vitamin K-dependent proteins (8, 9) .
The activation of bovine Factor IX by bovine Factor XIa (activated plasma thromboplastin antecedent) occurs in two steps (10, 11) . In the first step, a specific internal peptide bond is cleaved giving rise to a twochain intermediate held together by a disulfide bond(s). This intermediate does not have enzymatic activity. In the next step, a second specific peptide bond in the amino terminal region of the heavy chain is cleaved giving rise to Factor IXa5s and an activation peptide.
Bovine Factor IX is also activated by a protease from Russell's viper venom (RVV-X)2 in a single-step reaction (11) . In this reaction, Factor IX is activated by the cleavage of an internal arginyl-valine bond generating Factor IXaa. (11) . Recently, Osterud and Rapaport (12) have reported the activation of human Factor IX by Factor VII and thromboplastin. The details of this activation mechanism, however, have not been defined thus far.
Studies by a number of' investigators have shown ' The nomenclature for the various clotting factors is that recommended by an international nomenclature committee (13) . The nomenclature for activated Factor IX is that of Lind-(1uist et al. (11) . 2Abbreviations used in this paper: DFP, diisopropylphosphorofluoridate; RVV-X the protease from Russell's viper venom that activates Factor X. that the activation of' humilan Factor IX by humiiiani Factor XIa is similar to that of the bovine system (5, 14) . The (letails of this reactioni, howvever, have nlot I)een define(l. The primiairy objective of thiis work has been to investigate in detail the mechanisim of activation of' lihiuman Factor IX by htiuimani Factor XIa.
METHODS
Htimani Factor IX wvas ptirified to homogeneity by a slight modification of the metlhod of Di Scipio et al. (7) . In the present experimiients, a single 0-40% ammilonium stulf'ate precipitation w,as stubstittited for the se(qtiential 0-10% and 10-40% amimloniiium stilfate precipitations. The protease from RVV-X that activates Factor IX was purified to honiogenieitv by the method of Kisiel et al. (15 (7) , and this same value was assumed for Factor IXa. An E"", = 5.7 was employed for human antithrombin III (216), and an = 13.4 was assumed for human Factor XIa (18) .
Amino acid and carbohydrate analyses and preparation of samples were carried out by the methods described (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) .
Sodium dodecyl sulf;ate-polyacrylamide gel electrophoresis was performed by the method of Weber and Osborn (29) as modified by Kisiel et al. (15) . The gels were run for 3-4 h at 4.2 mA/gel and were stained for protein with a 0.2% solution of Coomassie Brilliant Blue. The gel containing the activation peptide was first fixed in 12.5% trichloroacetic acid for 1 h before staining. Molecular weights were estimated by interpolation from a linear semilogarithmic plot of molecular weight vs. migration distance with the following protein standards: phosphorylase b (97,000), bovine serum albumin (68,000), aldolase (40,000), bovine carbonic anhydrase (29,000), and myoglobin (17,000).
Activation ofFactor IX by Factor XIa and RVV-X Sepharose. Human Factor IX (10 mg) in 10 ml of 0.05 M Tris-HCl buffer, pH 7.8, containing 0.15 M NaCl and 5 mM CaCl2 was activated at 37°C by the addition of 0.13 mg Factor XIa. The enzyme-tosubstrate weight ratio varied from 1:50 to 1:80. The reaction was terminated by the addition of EDTA to a final concentration of 10 mM. For coagulant assays, samples (10 ,ul) were withdrawn at various times from the reaction mixture and diluted 100-to 1,000-fold with cold Michaelis buffer (36 mM sodium acetate, 36 mM sodium barbital, and 0.145 M sodium chloride, pH 7.4) containing bovine serum albumin (0.1 mg/ml). An aliquot (0.1 ml) of the diluted sample was then incubated at 37°C for 1 min with 0.1 ml of 0.08% inosithin suspension and 0.1 ml of normal human plasma in a siliconized glass tube. The clotting time was determined after the addition of 0.1 ml of 0.033 M CaCl2. The percent activation of Factor IX was determined from a calibration curve prepared from the folly activated sample.
Factor IX (0.056 mg) in 0.07 ml of 0.05 M Tris-HCl buffer, pH 7.8, containing 0.15 M NaCl and 10 mM CaCl2 was activated by the addition of 20 ul of RVV-X Sepharose suspension f'ollowed by rapid swirling throughout the incubation at 37°C. At various times, the reaction was terminated by the addition of 10 ,ul of' 0.2 M EDTA and the tube was centrif'uged for 1 min at 500 g to remove the RVV-X-Sepharose. Factor IXa in the supernatant fraction was then assayed as described above. The heavy and light chains of' human Factor IXa and the activation peptide were prepared as follows: Factor IX (10 mg) was incubated with Factor XIa (0.15 mg) for 75 min in the presence of 5 mM calcium chloride as previously described and the reaction was terminated by the addition of 1 ml of 0.2 M EDTA. The protein was then desalted on a Sephadex G-25 column (2 x 40cm) which had previously been e(quilibrated with 1% formic acid. The protein was eluted with 1% formic acid and the fractions containing the protein were pooled and lyophilized. It was then dissolved in 1 ml of 1% formic acid and 6 M urea and applied to a Sephadex G-75 column (1.6 x 84 cm) which had previously been e(quilibrated with 1% formic acid and 6.0 M urea. The flow rate was 0.1 ml/min. The peaks containing the activation peptide and Factor IXa were pooled separately and lyophilized. Factor IXa was then reduced and carboxymethylated or pyridylethylated by the methods of Crestfield et al. (23) or Friedman et al. (24) . The heavy and light chains were applied to a Sephadex G-50 superfine column (1.6 x 85 cm) which had previously been equilibrated with 1% formic acid and 6.0 M urea, and the column was eluted with the same solution. The flow rate was 0.2 ml/min. The peak containing the heavy chain was desalted on a Sephadex G-25 column (2 x 40 cm) in 10% formic acid and lyophilized. The peak containing the light chain was also desalted, lyophilized, and then redissolved in 6 M urea and 1% formic acid. It was then subjected to gel filtration on a second Sephadex G-50 column under the same conditions to free it from small amounts of contaminating heavy chain. After the second passage over the Sephadex G-50 column, the pure light chain was desalted and lyophilized.
The digestion of the heavy chain of Factor IXa by cyanogen bromide was performed by dissolving 9 mg of salt-free Spyridylethyl Factor IXa heavy chain in 1.5 ml of 70% formic acid. Cyanogen bromide (45 mg) was then added and the reaction was allowed to proceed for 36 h at 4°C. After lyophilization, the digest was fractionated by gel filtration on a Sephadex G-50 superfine column (2.6 x 95 cm) in 10% formic acid at a flow rate of 0.30 ml/min.
Amino terminal sequence analyses were performed with a Beckman sequenator model 890C (Beckman Instruments, Inc., Fullerton, Calif.) described (32) (33) (34) . For amino terminal analyses, the approximate amounts of samples that were used were 1.0 mg of the activation peptide, 1.5 mg of the Scarboxymethyl light chain of Factor IXa, 0.9 mg of the Spyridylethyl cyanogen bromide peptide containing the active site of Factor IXa, 1.5 mg of the S-pyridylethyl heavy chain of Factor IXa, and 0.8 mg of the third cyanogen bromide fragment from the digest of the heavy chain of Factor IXa. All analyses were performed twice. In the quantitation of the amino terminal residues, protein concentration was determined by amino acid analysis after hydrolysis of the sample in 6 N HCI. Norleucine was employed as the internal standard to calculate protein recovery.
Carboxyl terminal analysis was carried out by a modification of the procedure of Fraenkel-Conrat et al. (35) . Pancreatic carboxypeptidases A and B were treated with 1 mM DFP before use. The activation peptide (-0.5 mg) and the Scarboxymethylated light chain (_ 1.0 mg) were dissolved in 0.2 ml and 0.5 ml, respectively, of 0.01 NM sodium phosphate buffer, pH 8.0, containing 1.0% sodium dodecyl sulfate. The samples were boiled for 10 min and diluted by the addition of 0.25 ml or 0.5 ml of 0.01 M sodium phosphate buffer, pH 8.0, for the activation peptide and the S-carboxymethylated light chain, respectively. Half of the sample was incubated for 16 h at 37°C with carboxypeptidase A and the other half with carboxypeptidase B employing an enzyme-to-substrate weight ratio of 1:50. The liberated amino acids were then analyzed in the amino acid analyzer. The amount of the peptides was quantitated by amino acid analysis of a 24-h hydrolysate employing norleucine as an internal standard.
Antibodies against human Factor IX were prepared from rabbits which had been injected subcutaneously three times with 0.5-0.7 mg of purified human Factor IX with Freund's complete or incomplete adjuvant. The animals wvere bled by heart puncture and the antibodies were purified as described by Fujikawa et al. (36) . Immunoelectrophoresis was performed on glass slides (2.5 x 7.5 cm) with 1% agarose in 0.05 M sodium barbital buffer, pH 8.6, containing 0.01% sodium azide according to the method of Scheidegger (37) .
Samples (4-7 gg) were subjected to electrophoresis for 50 min at 150 V at 4°C and 50 ,lI of antibody solution (2.0 mg/ml) was added to the trough and allowed to diffuse through the agarose gel overnight. (Fig. 3) . In these experiments, aliquots were removed at various times from an activation reaction corresponding to those shown in Fig. 1 polyacrylamide gels with _mol wt 11,000 (Fig. 4 , insert, left panel). The first peak containing Factor IX,.p was then reduced, carboxymethylated (or pyridylethylated), and the chains were separated on a Sephadex G-50 superfine column (Fig. 4, right panel) . The heavy chain of Factor IXa., appeared in the first peak, and the light chain appeared in the second peak. These protein peaks also migrated as single bands on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Fig. 4, insert Table I . Amino acids that are underlined are identical to those found in bovine Factor IX (38) . The amino terminal sequence of the light chain was found to be Tyr-Asn-Ser-Gly-Lys-Leu. This sequence is identical to that found in the precursor molecule (7) . Table II . A summation of the amino acid and carbohydrate residues in the light chain (column 1) and the heavy chain (column 2) gives the composition for Factor IXa (column 3). Also, a summation of the composition of the light chain, the heavy chain, and the activation peptide (column 5) is in reasonably good agreement with that previously determined for the precursor protein (column 6). In these calculations, mol wt 18,000 was employed for the light chain, 28,000 for the heavy chain, and 11,100 for the activation peptide.
Factor IXa is also a glycoprotein, and the carbohydrate is located in both the light and heavy chains of the molecule. (38) indicate that a specific arginyl-alanine peptide bond and a specific arginyl-valine peptide bond are cleaved in Factor IX during the conversion of the precursor to Factor IXaa.
Amino acid sequience of the active site. To determine the amino acid sequeince in the active site region of human Factor IX, the S-pyridylethyl heavy chain of Factor IXa,, (9 mg) was subjected to eyanogen bromide digestion as described in Methods. The cyanogen bromide fragments were then fractionated on a Sephadex G-50 superfine column (2.5 x 95 cm) in 10% formic acid (Fig. 5) .Three major peaks were observed, which is consistent with the presence of' two methionine residues in the heavy chain of the molecule (Table II) . The first peak showed a shoulder on the leading edge of the peak, and this was found to be because of residual undigested heavy chain. Accordingly, the trailing edge of this peak and the remaining two peaks were pooled separately and lyophilized. The peptides recovered from peaks I, II, and III migrated as single bands on sodium dodecyl sulf'ate-polyacrylamide gel electrophoresis with -mol wt 18,000, 5,000, and 3,000, respectively. The amino terminal sequences of the three peptides and the e(quivaleints at each cycle are shown in Table I . The residues that are underlined are identical to residues from the corresponding region in bovine Factor IX (38 Activation of human Factor IX by a protease from RVV-X. A time-course for the activation of Factor IX by RVV-X-Sepharose is shown in Fig. 1 (solid circles) . Under the conditions employed, the reaction was essentially complete after [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 40 60 80 100 120 Froctlon Number FIGURE 5 Gel filtration of the cyanogen bromide peptides from the S-pyridylethyl heavy chain of human Factor IXae. The digest (9 mg) was dissolved in 2 ml of 25% formic acid and applied to a Sephadex G-50 superfine column (2.6 x 95 cm), which had been previously equilibrated with 10% foricii acid. The column was eluted with 10% formic acid at a flow rate of 0.3 ml/min, and 2.0 ml fractions were collected. The various peaks, as shown by the bars, were pooled individually, and the peptides were lyophilized. The sodium dodecyl sulfate-polyacrylamide gels of the second and third cyanogen bromide peptides are shown above their respective elution positions. The samples (-10 ,ug) were run on 10% gels for 4 h and stained with Coomassie Brillianit Blue. The anode was at the bottom of the gels.
-~~_ _N n t)<,r ., _~Am
Z~~~~~4
activated Factor IX formed in the reaction was called Factor IXaQ. Essentially, no activation of huiman factor IX by RVV-X-Sepharose occurred in the absence of calcium (solid triangles). RVV-X-Sepharose was employed in these experiments so that the clotting activity of Factor IXa could be readily followed after removal of the RVV-X-Sepharose by cenitrifugation. This was essential becatuse RVV-X readily activates Factor X and this reaction will mask the effect of Factor IXa in the clotting assay. The exact concentration of RVV-X in the reaction mixture was not determined. The enzyme-tosubstrate w,eight ratio was probably -1:25, because unbound RVVI-X at this enzyme-to-substrate ratio gave the same gel electrophoresis pattern as described below.
A change in Factor IX dturing the activation by RVV-X-Sepharose was observed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis. Fig. 7 shows the pattern of aliquots removed from the activationi mixtuLre at variouis tim-ies anid anialyzed by gel electrophoresis before anid after redtuction. At zero time, a single protein band (m-nol wt 57,000) was observed, and this band was the major band present after 20-30 min when near nmaximal Factor IXa, activity was obtained (Fig. 7, uipper band (-mol wt 46,000) was evident in these experiments, however, and this band migrated at a rate identical to Factor IXaO.
In reduced gels (Fig. 7, lower panel) , a new major protein band was observed with an _mol wt 28,000. These data suggested that the activation of Factor IX by RVV-X-Sepharose was a result of the cleavage of Factor IX into a two-chain molecule held together by a disulfide bond(s), and this molecule has the same molecular weight as the precursor. Upon reduction, the two-chain molecule is split into two chains that migrate at essentially the same rate on gel electrophoresis.
Evidence for the activation of Factor IX by a single cleavage of an internal peptide bond was shown by amino terminal sequence analysis of a reaction mixture incubated for -30 min under conditions analogous to those shown in Fig. 1 . Under these conditions, >80% of the activated Factor IX was Factor IXa, and <20% was Factor IXas as determined by gel electrophoresis.
In the first turn in the amino acid sequencer, valine and tyrosine in equal amounts were identified and little, if any, alanine was present. In subsequent turns, the following residues were identified: asparagine and valine in cycle two, serine and glycine in cycle three, glycine in cycle four, and lysine and glutamic acid in cycle five. These residues correspond to the Tyr-Asn-SerGly-Lys sequence in the amino terminal chain of the precursor molecule and the Val-Val-Gly-Gly-Glu sequence of the heavy chain of Factor IXaO, as previously determined. These data indicated that the conversion of human Factor IX to Factor IXaat by RVV-X-Sepharose is a result of the cleavage of a single internal peptide TYR ASN SER ( bond, and this bond is the same as that cleaved in Factor IX by Factor XIa. These data also suggest that Factor IXao is converted slowly to Factor IXa,, and this reaction is probably due to the removal of the same activation peptide which is released during the activation of Factor IX by Factor XIa.
DISCUSSION
In the present experiments, it has been shown that human Factor IX is readily converted to Factor IXaI in the presence of human Factor XIa and calcium ions. This reaction involves a two-step mechanism that is illustrated in Fig. 8 acid sequence in this region shows considerable homology with bovine Factor IX as well as many other plasma serine proteases (39, 40) . Human Factor IX is also activated by a protease from RVV-X. This enzyme initially cleaves the internal ArgVal bond giving rise to Factor IXaa (Fig. 8) . Factor IXaaX is composed of a heavy and a light chain held together by a disulfide boind(s) and has the same molecular weight as the precursor. Also, it has about the same specific clotting activity as Factor IX-. With the bovine system, Factor IXa, has -50% of the clotting activity of Factor IX,,o (11) . On prolonged incubation with RVV-X, human Factor IXa, undergoes a further cleavage and appears to be converted to Factor IXs3 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This reaction, however, was not examined in detail.
The critical event in the activation of Factor IX by Factor XIa or RVV-X is the cleavage of the internal Arg-Val bond. This cleavage very likely permits the formation of a new ion pair between the valine residue and the aspartic acid residue adjacent to the active site serine. This would be analogous to the activation mechanism which has been established for the pancreatic serine proteases (41, 42 ). An aspartic acid residue also appears six residues before the active site serine in pancreatic trypsin. This aspartic acid residue is located in the bottom of the binding pocket in this enzyme and is responsible for the specificity of trypsin for peptides containing basic amino acids (43) (44) (45) (46) (47) (48) . Thus, it seems likely that the specificity of Factor IXa toward peptides containing a basic amino acid is due to a similar mechanism.
The bond(s) that is cleaved in Factor IX by Factor VII and thromboplastin is not known (12) . Also, the exact bond(s) that is cleaved in Factor IX by Factor Xa has not been established (11, 49) . It seems likely that the activation of Factor IX by these enzymes also involves the cleavage of the same Arg-Val bond that is cleaved by Factor XIa and RVV-X. Factor VII and thromboplastin, as well as RVV-X, also activate Factor X (1). It appears very probable, however, that the primary effect of RVV-X on the clotting of whole plasma is a result of its effect on Factor X rather than Factor IX. This is indicated by the fact that Factor X is activated by RVV-X at a rate 10-20 times faster than the activation of Factor IX by RVV-X. Furthermore, the specific activity of Factor Xa in a clotting assay is 100-300 times greater than that of Factor IXa (11, 50) , and RVV-X corrects Factor IX-deficient plasma at the same rate as it corrects Factor IXdeficient plasma reconstituted with purified Factor IX. 3 Whether the major effect of Factor VII and thromboplastin on whole plasma is toward Factor IX or Factor X is not known. It should also be pointed out that the 3Di Scipio, R. Unpublished results.
primary effect of Factor Xa on clotting of plasma is in the activation of prothrombin rather than Factor IX. This is indicated by the high specific activity of Factor Xa relative to Factor IXa in a clotting assay as well as by the fact that Factor Xa corrects Factor IX-deficient plasma at the same rate as it corrects Factor IX-deficient plasma reconstituted with purified Factor IX. 3 The effect of antithrombin III on Factor IXa has also been studied in the present investigations confirming earlier experiments with human and bovine Factor IXa (5, 31) . The present data have also clearly demonstrated the formation of a one-to-one molar complex of enzyme and inhibitor, and the formation of this complex was shown to occur via the heavy chain of the enzyme. The nature of the linkage between enzyme and inhibitor, however, is not known.
